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Introduction
33 TGF-–related proteins orchestrate a broad spectrum of de-
velopmental and physiological processes in mammals (Katagiri 
et al., 2008). Multiple mechanisms that operate within and out-
side the cell and at the cell surface regulate signaling by TGF- 
family members in a context-specific manner (Shi and Massagué, 
2003; ten Dijke and Arthur, 2007; Kang et al., 2009). Extra-
cellular control of endogenous (local) TGF- signaling, in par-
ticular, is emerging as an important aspect of organ formation   
and tissue homeostasis (Ramirez and Rifkin, 2009). TGF-1, -2, 
and -3 (hereafter collectively referred to as TGF-) are secreted 
either as a small latent complex (SLC) in which the bioactive 
homodimer remains associated with the processed propeptides 
(latency-associated protein [LAP]) or as a large latent complex 
(LLC) in which the SLC is bound to latent TGF-–binding pro-
teins (LTBPs) 1, 3, or 4 (Annes et al., 2003). LAP association 
blocks ligand interaction with TGF- receptors, whereas LTBP 
binding targets the SLC to the ECM through LTBP-mediated   
association with fibronectin or fibrillin assemblies (microfibrils). 
Several extracellular molecules (many of which interact with 
microfibrils) and integrin receptors are involved in releasing 
TGF- from the ECM, disrupting LAP-mediated latency, or in-
hibiting TGF- activity. Bone morphogenetic proteins (BMPs), 
too, are secreted and targeted to the ECM as C-terminal di-
sulfide cross-linked dimers that are noncovalently associated 
E
xtracellular regulation of signaling by transforming 
growth factor (TGF)– family members is emerging 
as  a  key  aspect  of  organ  formation  and  tissue   
remodeling. In this study, we demonstrate that fibrillin-1 
and -2, the structural components of extracellular micro-
fibrils, differentially regulate TGF- and bone morpho-
genetic protein (BMP) bioavailability in bone. Fibrillin-2–null 
(Fbn2
/) mice display a low bone mass phenotype that 
is associated with reduced bone formation in vivo and   
impaired osteoblast maturation in vitro. This Fbn2
/ 
phenotype is accounted for by improper activation of latent 
TGF- that selectively blunts expression of osterix, the 
transcriptional regulator of osteoblast maturation, and 
collagen I, the structural template for bone mineralization. 
Cultured osteoblasts from Fbn1
/ mice exhibit improper 
latent TGF- activation as well, but mature faster because 
of increased availability of otherwise matrix-bound BMPs. 
Additional in vitro evidence excludes a direct role of micro-
fibrils in supporting mineral deposition. Together, these 
findings identify the extracellular microfibrils as critical 
regulators of bone formation through the modulation of 
endogenous TGF- and BMP signaling.
Fibrillin-1 and -2 differentially modulate  
endogenous TGF- and BMP bioavailability  
during bone formation
Harikiran Nistala,
1 Sui Lee-Arteaga,
1 Silvia Smaldone,
1 Gabriella Siciliano,
1 Luca Carta,
1 Robert N. Ono,
2,3  
Gerhard Sengle,
2,3 Emilio Arteaga-Solis,
4 Regis Levasseur,
5 Patricia Ducy,
5 Lynn Y. Sakai,
2,3 Gerard Karsenty,
5  
and Francesco Ramirez
1
1Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10021
2Shriners Hospital for Children and 
3Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR 97239
4Division of Pulmonary Medicine, Department of Pediatrics and 
5Department of Development and Genetics, College of Physicians and Surgeons, Columbia University,  
New York, NY 10029
©  2010  Nistala  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 190 • NUMBER 6 • 2010   1108
Furthermore, they exclude a direct contribution of microfibrils 
to the formation of the organic substrate that supports mineral 
deposition in bone. Collectively, these findings significantly 
advance our understanding of the extracellular control of local 
TGF- and BMP signaling in bone physiology.
Results
Loss of fibrillin-2 leads to decreased  
bone mass
Fbn2
/ mice are viable and fertile but proportionally smaller 
than wild-type (WT) littermates throughout life and irrespective 
of gender (Arteaga-Solis et al., 2001). Consistent with this last 
observation, a modest but statistically significant (P < 0.003) 
length reduction (4.5%) was recorded in 4-mo-old Fbn2
/  
femurs compared with WT counterparts (n = 10 for each geno-
type). Additionally, morphometric analyses of mid-diaphyseal 
cross sections of 1-mo-old mutant femurs identified changes 
in bone shape that were appreciably more evident in 4-mo-old 
Fbn2
/ mice. Changes in the latter set of mutant femurs in-
cluded a 15% smaller bone width (P < 0.0003) and a 25% nar-
rower marrow cavity than WT specimens (n = 7). In contrast, 
4-d-old (postnatal day [P] 4) Fbn2-null femurs were normally 
shaped  and  displayed  morphologically  unremarkable  growth 
plates (unpublished data), implying a probable defect in post-
natal bone modeling rather than an abnormality in endochon-
dral bone development.
Consistent  with  the  aforementioned  prediction,  micro-
computed tomography (µCT) and histomorphometric analyses 
detected an appreciable deficit of cancellous bone in 3- and   
6-mo-old mutant vertebrae. To be specific, examination of the 
former samples (n = 5) revealed a 58% decrease in bone mineral 
density (bone mineral content/total volume [TV]; P = 0.0007), a 
27% decrease in bone mass (bone volume [BV]/TV; P = 0.0008; 
Fig. 1 A), and 52% fewer trabeculae (P < 0.003) and 66% 
greater intertrabecular space (P < 0.01). Parallel in vivo analyses 
showed a 55% reduction in bone formation rate (BFR; n = 6; 
P = 0.0003) associated with a seemingly normal complement 
of osteoblasts (number of surface osteoblasts/bone perimeter;   
n = 5; P = 0.24) in mutant compared with WT mice (Fig. 1 B). 
Altogether, these static and dynamic assessments strongly sug-
gested that impaired bone formation is a major determinant of 
osteopenia in Fbn2
/ mice.
Loss of fibrillin-2 impairs  
osteoblast maturation
In line with the in vivo data, Fbn2-null calvarial osteoblasts 
(cObs) or marrow stromal cells (MSCs) cultured with osteo-
inductive supplements (OSs) yielded fewer and smaller miner-
alized nodules than the WT counterparts (Fig. 2 A). Impaired 
osteoblast maturation is characterized by a progressively mod-
est reduction in AP activity (Fig. 2 B) and by an appreciable   
decrease in collagen deposition (as visualized by van Gieson 
counterstaining of mutant cOb cultures; Fig. 2 A). Quantitative 
real-time RT-PCR (qPCR) assays confirmed a substantial down-
regulation of 2(I) collagen (Col1a2) and osteocalcin (Bglap1; 
a marker of terminal osteoblast differentiation) in mutant cOb in 
with the N-terminal propeptides (Katagiri et al., 2008). However, 
in contrast to TGF-, in vitro bioactivity assays suggest that 
BMP prodomains generally may not confer latency to the asso-
ciated dimers (Sengle et al., 2008a). Moreover, the factors and 
mechanisms that control BMP sequestration in and release from 
the ECM are less well understood than those regulating TGF-  
bioavailability. Earlier characterization of a limb-patterning 
defect (syndactyly) in mice with inactivated fibrillin-2 gene 
(Fbn2) expression revealed a genetic interaction between this 
ECM molecule and BMP7 signaling in the forming autopods 
(Arteaga-Solis et al., 2001). Subsequent in vitro experiments 
demonstrated that BMP prodomains can directly interact with 
the N termini of fibrillin-1 and -2 (Sengle et al., 2008b).
Fibrillin microfibrils are ubiquitous architectural elements 
of the ECM that endow connective tissues with specific physical 
properties, either as obligatory constituents of elastic fibers or as 
elastin-free assemblies (Ramirez and Rifkin, 2009). Fibrillins 
interact with several ECM proteins during microfibril biogene-
sis, and many of these interactions occur at or near the same 
sites of LLC and BMP binding (Ramirez and Sakai, 2010). The 
pleiotropic manifestations of Marfan syndrome (MFS; OMIM-
154700) and congenital contractural arachnodactyly (CCA; 
OMIM-121050), which are caused by mutations in fibrillin-1 
and -2, respectively, underscore the importance of fibrillin micro-
fibrils in the formation and function of several organ systems 
(Ramirez and Dietz, 2007). Moreover, the distinct phenotypes 
of MFS and CCA imply that fibrillin-1 and -2 have discrete 
functions in spite of them being the building blocks of the same 
matrix assemblies. Consistent with this postulate, Fbn1
/ mice 
do not share the limb-patterning defect of Fbn2
/ mice that 
was genetically associated with low BMP7 signaling (Arteaga-
Solis et al., 2001; Carta et al., 2006), and aortic wall homeo-
stasis is severely impaired only in Fbn1 mutant mice largely as 
a result of promiscuous TGF- signaling (Pereira et al., 1999; 
Judge et al., 2004; Habashi et al., 2006). Thus, fibrillin-1 and -2 
may control local TGF- and BMP bioavailability differently, 
depending on the organ system, developmental stage, or physio-
logical program.
The scope of this study was to test the aforementioned   
hypothesis using bone formation as an informative model sys-
tem because of the following considerations. First, osteogenesis 
is a fairly well understood process that can be replicated in vitro 
using primary osteoblast cultures (Stein et al., 1990; Karsenty   
et al., 2009). Second, TGF- and BMPs are abundantly stored in 
the bone matrix from which they are released in a timely fashion   
and at the appropriate concentration to regulate osteogenic dif-
ferentiation (Rosen and Thies, 1992; Mundy et al., 1995; Katagiri 
et al., 2008). Third, Fbn1 and Fbn2 are highly expressed in the 
progenitor and differentiating osteoblasts of forming and adult 
bones (Zhang et al., 1994, 1995; Kitahama et al., 2000; Arteaga-
Solis et al., 2001; Quondamatteo et al., 2002; Roman-Roman   
et al., 2003; Ulloa-Montoya et al., 2007). Fourth, low bone mass 
(osteopenia) is one of the few clinical manifestations in com-
mon between MFS and CCA patients (Ramirez and Arteaga-
Solis, 2008). Our experiments demonstrate that fibrillin-2 and -1 
regulate osteoblast maturation by controlling TGF- bioavail-
ability and calibrating TGF- and BMP levels, respectively. 1109 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
statistically significant because of an outlier in the latter set of 
samples (Fig. 3 D). This point notwithstanding, we concluded 
that loss of fibrillin-2 delays osteoblast maturation by selectively 
interfering, presumably in an osterix-dependent manner, with 
the differentiation program that normally promotes maturation 
and mineralization of the bone ECM.
Latent TGF- is improperly activated in 
Fbn2-null osteoblast cultures
Previous evidence implicating fibrillin-1 in the extracellular con-
trol of TGF- signaling (Isogai et al., 2003; Neptune et al., 2003) 
prompted us to investigate whether fibrillin-2 is involved in this reg-
ulatory process as well. To this end, interactions between fibrillin-2   
and LTBPs 1 and 4 were first evaluated in vitro using surface plas-
mon resonance and recombinant peptides that correspond to the 
N-terminal segment of fibrillin-2 (rF86) and the C-terminal se-
quences of LTBPs 1 and 4 (L1K and L4K). The BIAcore assays 
established that the rF86 fragment binds the L1K and L4K peptides 
with the same high affinity (Kd = 20–25 nM), as previously shown 
for the corresponding N-terminal segment of fibrillin-1 (Fig. 4 A; 
Ono et al., 2009). Next, Fbn2-null cObs were found to display a 
greater ALK5-dependent nuclear accumulation of pSmad2 (phos-
phorylated Smad2) than WT cells (Fig. 4 B). Furthermore, relative 
levels of pSmad2/3 proteins and transcriptional activity of a trans-
fected TGF-–inducible plasmid (p3TP-lux) were both apprecia-
bly higher in mutant than control cells (Fig. 4 C and Fig. S1 A). 
Lastly, the TMLC bioassay (epithelial cells stably transfected with 
p3TP-lux; Abe et al., 1994) revealed more active TGF- but nearly 
normal amounts of total TGF- in Fbn2-null compared with WT 
cOb cultures (Fig. 4 D). The latter finding was independently sup-
ported by qPCR analyses showing normal steady-state levels of 
Tgf- transcripts in Fbn2-null osteoblasts (Fig. 4 E).
addition to excluding a compensatory up-regulation of Fbn1 
(Fig. 2 C). The qPCR assays also correlated impaired matura-
tion of Fbn2-null cOb cultures with lower than normal activity 
of the osterix gene (Osx), which encodes a transcriptional regu-
lator of osteoblast differentiation (Nakashima et al., 2002), and 
with unremarkable levels of Runx2 mRNA, which encodes   
the transcriptional determinant of osteoprogenitor commitment 
(Fig. 2 C; Ducy et al., 1997). Identical results were obtained with 
RNA purified from the calvariae of Fbn2
/ newborns (Fig. 2 C). 
Lastly, no significant differences in cell proliferation, BrdU in-
corporation, and C-myc and Ccnd1 (cyclin D1) mRNA levels 
were noted between mutant and WT cOb cultures 3 d before and 
at the time of OS treatment (Fig. 2, D and E). Similar results 
were obtained by comparing cell survival and apoptosis of   
mutant and control cOb cultures (Fig. 2, F and G).
In vivo and ex vivo cell-marking experiments confirmed the 
aforementioned maturation defect by showing a substantial re-
duction in the number of GFP-positive cells in neonatal bones and 
cOb cultures from Fbn2
/ mice harboring the pOBCol2.3GFP 
transgene, which is specifically activated during osteoblast mat-
uration (Fig. 3; Kalajzic et al., 2005).  Incidentally, GFP marking 
confirmed that fewer surface osteoblasts are actively producing 
collagen I in mutant bones (Fig. 3 B). Likewise, fewer GFP-
positive cells in cOb cultures from Fbn2
/ mice harboring the 
Osx1-GFP::Cre transgene reiterated the negative impact of the mu-
tation on this critical regulator of osteoblast maturation (Fig. 3 C). 
Importantly, however, the finding that Fbn2-null cOb cultures 
can respond to the osteoinductive signal of exogenously added 
BMP2 by restoring Osx and Col1a2 activity and improving min-
eral nodule formation demonstrated the reversible nature of the 
cell defect (Fig. 3 D). Incidentally, the 10% greater matura-
tion of BMP2-treated compared with untreated WT cOb was not 
Figure  1.  Reduced  bone  mass  and  BFR  in 
Fbn2
/  mice.  (A)  Representative  von  Kossa 
staining and µCT images of vertebral sections 
from  3-mo-old  WT  and  Fbn2
/  male  mice 
with  histograms  summarizing  the  µCT  mea-
surements of volumetric bone mineral density 
(BMD) and BV/TV in these samples. (B) Illustra-
tive examples of dual-calcein labeling in tibiae 
of 3-mo-old WT and Fbn2
/ male mice with 
histograms summarizing BFR values and osteo-
blast numbers in WT and mutant samples. 
Error bars indicate mean ± SD, and asterisks 
indicate  statistically  significant  differences   
(P < 0.05) between genotypes. Bars, 50 µm.JCB • VOLUME 190 • NUMBER 6 • 2010   1110
Figure 2.  Impaired maturation of Fbn2-null osteoblasts. (A) Illustrative images of von Kossa staining of neonatal cOb (left) and adult MSCs (right) along 
with magnified van Geison–counterstained images (middle) of cOb differentiated for 21 d after OS administration. Histograms summarize the number of 
mineralized nodules in WT and Fbn2-null (Fbn2
/) cOb (n = 15) and MSC (n = 5) cultures. Bars, 200 µm. (B) AP activity of WT and Fbn2
/ cOb mea-
sured 3 d before (day 3) and 4 d after (day 4) OS administration (day 0) and normalized to total protein levels (n = 5). (C) qPCR estimates of indicated 
transcripts in total RNA isolated from day 4 cOb cultures (n = 4; top) or P4 calvariae of WT and Fbn2
/ mice (n = 4; bottom). (D and E) MTT and BrdU 
incorporation assays (D) and C-myc and Ccnd1 mRNA levels (E) at the indicated days of cOb differentiation (n = 6). (F and G) Cell survival evaluated by 
Trypan blue exclusion (F; n = 4) and cell apoptosis (G) measured as the fraction of cleaved caspase-3 over full-length protein (with histograms represent-
ing densitometric analyses) in WT and mutant cObs. Error bars indicate mean ± SD, and asterisks indicate statistically significant differences (P < 0.05) 
between genotypes.1111 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
to the amount extracted from cells) of mutant compared with 
WT samples (n = 3; P < 0.0001). Furthermore, qPCR analyses 
showed  that  Ltbp1  mRNA  accumulation  in  differentiating 
mutant cOb (time points at days 0, 3, and 7 of osteoinduction) 
is less than control (14%) only 3 d after OS treatment (n = 3;   
P < 0.046). Taken at face value, these results strongly suggested 
Because LTBPs target TGF- to microfibrils (Isogai et al., 
2003), we examined LTBP1 incorporation in the matrix laid 
down by overconfluent cOb cultures and found less immuno-
reactive material in Fbn2-null than WT cultures (Fig. 5 A). TMLC 
bioassays correlated this visual finding with an 47% decrease 
in the amount of TGF- extracted from the matrix (relative 
Figure 3.  Osterix and collagen down-regulation in Fbn2-null osteoblasts. (A and C) Illustrative images of pOBCol2.3GFP (A) or Osx-GFP::Cre transgene 
expression (C) in Fbn2-null and WT cOb at day 17 or 4 of differentiation, respectively, with histograms summarizing the number of GFP-positive cells   
(n = 3); nuclei are DAPI stained. (B) Illustrative images of tibiae of Fbn2
/ and WT mice harboring the pOBCol2.3GFP transgene that include (from top to 
bottom) hematoxylin/eosin staining, GFP expression, and magnified views of toluidine- and GFP-positive cells; histograms summarize cell counts in the last 
images (n = 3). (D) von Kossa staining after 21 d of differentiation of cOb treated with or without 100 ng/ml rhBMP2 with histograms (right) summarizing 
numbers of mineralized nodules and levels of Osx and Col1a2 transcripts in mutant and WT samples (n = 3). Error bars indicate mean ± SD, and asterisks 
indicate statistically significant differences (P < 0.05) between genotypes. Bars: (A and B [middle]) 100 µm; (B [top and bottom] and C) 50 µm.JCB • VOLUME 190 • NUMBER 6 • 2010   1112
Figure 4.  Fibrillin-2 controls TGF- bioavailability. (A) Surface plasmon resonance sensograms of binding of immobilized L1K (left) and L4K (right) to rF86 
at concentrations between 0 (baseline tracing) and 200 nM (top tracing). Binding was recorded as resonance units (RU), and nonspecific binding to control 
surface was subtracted at a molar ratio of 1:1. The table summarizes the affinity data (expressed as Kd) for interactions between the LTBPs and fibrillin-2 
peptide. (B) Immunodetection of nuclear pSmad2 accumulation in day 4 cOb cultured in low serum with or without SB431542; nuclei are DAPI stained. 
Histograms summarize the percentage of pSmad2-positive nuclei in WT (black) and mutant (gray) cells (n = 3). (C) Transcriptional activity of p3TP-lux 
reporter plasmid transfected in WT or Fbn2-null cOb cultured in low serum (n = 3). (D) TMLC bioassays (n = 5) measuring active TGF- in WT or Fbn2-null 
cOb cultures (left) or total TGF- in heat-activated conditioned media of the same cultures (right). (E) qPCR estimates of Tgf- transcripts in WT and Fbn2-null 
cOb (n = 3). Error bars indicate mean ± SD, and asterisks indicate statistically significant differences (P < 0.05). Bars, 50 µm.1113 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
are abundantly deposited in the ECM of the forming autopods 
(Arteaga-Solis et al., 2001; Carta et al., 2006).
To test the postulated involvement of improper TGF- 
signaling, mineral nodule formation was assessed in Fbn2-null 
cOb cultures that were induced to differentiate in the presence 
of either an ALK5 kinase inhibitor or a pan–TGF-–neutralizing 
antibody or that were transfected with siRNA against Alk5  
before OS treatment. Inhibition of TGF- signaling by any of 
that  loss  of  fibrillin-2  promotes  improper  TGF-  activation 
mostly by impairing LLC sequestration in the osteoblast matrix. 
Decreased matrix incorporation of LTBP1 in the presence of   
robust Fbn1 expression further suggested that fibrillin-1 could 
not compensate for the loss of fibrillin-2 deposition in differ-
entiating cOb cultures. This last observation is analogous to the 
previous finding that the BMP-dependent syndactyly of Fbn2
/ 
mice is not seen in Fbn1
/ mice even though both proteins 
Figure  5.  Elevated  TGF-  signaling  limits 
Fbn2-null  osteoblast  maturation.  (A)  Illustra-
tive images of immunoreactive material corre-
sponding to the indicated proteins deposited in 
the ECM of overconfluent WT, Fbn1-null, and 
Fbn2-null cOb cultures after 4 d of differen-
tiation; nuclei are DAPI stained. Bars, 50 µm.   
(B) Maturation of WT and Fbn2-null cOb cul-
tures treated with 1 µM SB431542, 300 ng/ml   
neutralizing  pan–TGF-  antibody,  or  50  µM 
Alk5  siRNA  with  histograms  summarizing 
the  number  of  mineralized  nodules  in  each 
treatment (n = 3). (C) qPCR estimates of the 
indicated mRNA levels in the Alk5 silencing 
experiments. Error bars indicate mean ± SD, 
and  asterisks  indicate  statistically  significant 
differences (P < 0.05).JCB • VOLUME 190 • NUMBER 6 • 2010   1114
Furthermore, qPCR analyses identified no significant differ-
ences in the steady-state levels of several Bmp transcripts be-
tween WT and Fbn1- or Fbn2-null cOb (Fig. 7, D and E). Lastly, 
ELISA assays estimated that BMP levels are appreciably higher 
in Fbn1-null than WT conditioned media and appreciably lower 
in Fbn1-null compared with WT matrices (109 vs. 81 pg/ml and 
827 vs. 903 pg/ml, respectively; n = 3; P < 0.01). Collectively, 
these results suggested that loss of fibrillin-1 deposition impairs 
BMP sequestration in the ECM with the consequence of increas-
ing BMP signaling and, thus, overriding the inhibition of osteo-
blast maturation by promiscuous TGF- signaling.
Although the reason why a similar elevation of BMP sig-
naling was not observed in Fbn2-null osteoblasts is yet to be de-
termined, the cell culture experiments at least clarified whether 
or not the increases in TGF- and BMP signaling that character-
ize Fbn1-null cOb are causally related to each other. BMP bio-
assays revealed that conditioned media from Fbn1-null cOb 
cultures stimulate C2C12BRA reporter cells twofold more than 
those from control or Fbn2-null cells and that this increase can 
be abrogated by adding the BMP antagonist noggin to the media, 
but not by using conditioned media from Fbn1-null cOb pre-
treated with the ALK5 inhibitor SB431542 (Fig. 7 C). Conversely, 
addition of noggin to Fbn1-null cOb cultures transfected with 
p3TP-lux did not affect expression of the TGF-–responsive re-
porter plasmid (Fig. 6 F). These results therefore excluded the 
possibility that augmented TGF- activity in Fbn1-null cOb cul-
tures stimulates BMP signaling and vice versa. An implicit cor-
ollary to this conclusion is that fibrillin-1 is directly involved in 
calibrating the bioavailability of both TGF- and BMP mole-
cules during bone formation. Moreover, dysregulated TGF- 
and BMP signaling in Fbn1-null bones is a tissue-specific trait   
in that only the former signaling abnormality characterizes the   
aortic media and vascular smooth cell cultures of Fbn1
/ mice, 
and neither of them is evident in the skin or dermal fibroblast 
cultures of the same mutant animals (Carta et al., 2006, 2009; 
unpublished data).
Fibrillin microfibrils are not structural 
components of the mineralization-
competent matrix
Although the aforementioned data implicated fibrillin-1 and -2 
in the differential control of local TGF- and BMP signals dur-
ing bone formation, they did not formally exclude the possibil-
ity that microfibrils may also be required to form the organic 
substrate promoting ECM mineralization (Murshed et al., 2005). 
Accordingly, the mineralizing potential of the microfibril-deficient 
bone matrix was assessed by the siRNA approach to circumvent 
the problem of embryonic lethality of mice deficient for both 
fibrillins (Carta et al., 2006). To this end, maturation of Fbn1- 
or Fbn2-silenced WT cOb was first equated with the respective 
phenotypes of Fbn1- or Fbn2-null cells (Fig. 8 A). This find-
ing further corroborated the cell (culture)-autonomous nature 
of the fibrillin mutations. Next, Fbn1 silencing was shown to 
improve mineral nodule formation in Fbn2-null cOb cultures 
(Fig. 8 B). Mineral nodule formation in cOb cultures lacking 
both fibrillin proteins was therefore interpreted to exclude a 
major structural role of microfibrils in directly supporting bone 
these three strategies equally improved maturation of Fbn2-null 
cOb (Fig. 5 B). Phenotypic rescue of Alk5-silenced mutant cOb 
was further associated with normalization of Osx and Col1a2 
transcript levels (Fig. 5 C). These results were therefore inter-
preted to indicate that improper activation of latent TGF- sec-
ondary to loss of fibrillin-2 impairs bone formation by interfering 
specifically with the ability of osteoblasts to assemble a miner-
alization-competent bone matrix. Normal TGF- signaling 
in another microfibril-rich tissue (skin) and fibrillin-producing 
cells (dermal fibroblasts) of Fbn2
/ mice indirectly validated 
the specific effect of the mutation in osteoblasts and bone 
(unpublished data).
TGF- and BMP signaling are both 
abnormally high in Fbn1-null osteoblasts
Although neonatal lethality of Fbn1
/ mice limits performing 
extensive analyses of bone formation (Carta et al., 2006), these 
mutant animals nonetheless enabled us to compare and contrast 
osteogenic differentiation on a matrix deficient for either fibrillin-1   
or -2. Fbn1-null cOb proliferated normally but, in contrast to 
Fbn2-null cells, they yielded more mineral nodules than WT cul-
tures (Fig. 6, A and B); they also displayed a modest increase in 
Osx expression, a significant up-regulation of Col1a2 and Bglap1, 
and normal Runx2 and Fbn2 activity (Fig. 6 C). In vivo levels 
of Col1a2 and Bglap1 (but not Osx) transcripts were apprecia-
bly higher than control, and collagen accumulation was slightly 
greater in mutant than WT bones (Fig. 6 D and Fig. S1 C). More-
over, AP-positive cells and mineral deposits appeared earlier and 
grew faster in Fbn1-null than WT cOb cultures (Fig. S1 D). Col-
lectively, these observations were consistent with the notion that 
loss of fibrillin-1 accelerates osteoblast maturation.
Similar to Fbn2-null cells, Fbn1-null cOb cultures dis-
played less LTBP1-immunoreactive material, more activated 
TGF-, and greater p3TP-lux activity than WT cultures (Fig. 5; 
and Fig. 6, E and F). Normal amounts of total TGF- and nor-
mal levels of Tgf- transcripts further corroborated the notion 
that loss of fibrillin-1 deposition leads to improper activation of 
latent TGF- complexes (Fig. 6, E and G). Additionally, normal 
responses of Fbn1-null cOb cultures to the opposing signals of 
recombinant TGF-1 and BMP2 excluded possible changes of 
cell identity (Fig. S1 E). These findings raised the question   
of which factors may be responsible for overriding the negative 
impact of heightened TGF- signaling on osteoblast matura-
tion. We reasoned that BMPs were obvious candidates because 
they are potent osteoinductive factors that interact in vitro with 
fibrillin-1 (Sengle et al., 2008b).
Two sets of evidence supported our hypothesis. First,   
immunofluorescence microscopy documented greater accumula-
tion of pSmad1/5/8 in the nuclei of Fbn1-null cOb than in those 
of control or Fbn2-null cells (Fig. 7 A). These visual data were 
correlated with seemingly more pSmad1/5/8 proteins and higher 
BRE-luc activity in Fbn1-null cOb cultures compared with the 
WT or Fbn2-null counterparts (Fig. 7 B and Fig. S1 B). Second, 
BMP bioassays revealed that conditioned media from Fbn1-null 
cOb cultures stimulate C2C12BRA reporter cells (which harbor 
the BMP-inducible plasmid BRE-luc; Zilberberg et al., 2007) 
twofold more than control or Fbn2-null media (Fig. 7 C). 1115 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
of bone mass by balancing the pools of progenitor and ma-
ture osteoblasts (Mundy et al., 1995). It also identifies fibrillin   
microfibrils as the architectural elements of bone tissue that 
are principally involved in the storage of TGF- and BMP 
complexes. Specifically, our experiments have shown that 
promiscuous TGF- signaling is the cell-autonomous pheno-
type of primary osteoblast cultures derived from the bones 
of either Fbn1
/ or Fbn2
/ mice; they have established 
that unopposed TGF- signaling in differentiating Fbn2-null   
osteoblasts selectively inhibits osterix and collagen I produc-
tion; they have implied that fibrillin-1 deposition in the forming 
mineralization. Incidentally, little or no LTBP1-immunoreactive 
material in Fbn2-null cOb silenced for Fbn1 supported prior 
evidence  indicating  that  fibronectin  and  fibrillin  assemblies 
are sequentially involved in incorporating LTBPs in the ECM   
(Fig. S2; Dallas et al., 2005).
Discussion
This study provides genetic validation for the long-held be-
lief that sequential release of TGF- and BMP ligands from 
the bone matrix contributes to the physiological maintenance 
Figure 6.  Abnormally high TGF- activity in differentiating Fbn1-null osteoblasts. (A) Illustrative images of von Kossa–stained WT and Fbn1-null (Fbn1
/) 
cOb after 21 d of differentiation with histograms summarizing the number of mineralized nodules in each sample (n = 5). (B) Cell proliferation of WT and 
mutant cOb at day 3 of cell culture as assessed by BrdU incorporation and qPCR quantification of C-myc and Ccnd1 transcripts (n = 3). (C and D) qPCR 
estimates of indicated transcripts in total RNA isolated from day 4 differentiating WT and mutant cOb cultures (C; n = 4) and from P4 WT and Fbn1
/ 
calvarial bones (D; n = 3). (E) TMLC bioassays (n = 5) measuring active TGF- in WT or Fbn1-null cOb cultures (left) or total TGF- in heat-activated condi-
tioned media of the same cultures (right). (F) Transcriptional activity of p3TP-lux reporter plasmid transfected in WT or Fbn1-null cOb cultured in low serum 
with or without 1 µg/ml of noggin (n = 3). (G) qPCR estimates of TGF- transcripts in WT and Fbn2-null cOb (n = 3). Error bars indicate mean ± SD, and 
asterisks indicate statistically significant differences (P < 0.05).JCB • VOLUME 190 • NUMBER 6 • 2010   1116
Cell culture experiments have indicated that TGF- and 
BMPs have both overlapping and opposing functions in bone 
formation. On the one hand, TGF- stimulates the recruitment 
and proliferation of osteoblast progenitors but inhibits their ter-
minal differentiation; and on the other hand, BMPs cooperate in 
the former process in addition to promoting osteogenic commit-
ment of MSCs and osteoblast maturation (Alliston et al., 2008). 
However, albeit informative, these in vitro analyses have used 
exogenous stimulators or inhibitors of cell signaling and differ-
entiation to infer the dynamics of locally released TGF- and 
BMP signals during bone formation. For example, increased dif-
ferentiation of C2C12 cells treated with BMP4 in the presence 
of an ALK5 inhibitor was interpreted to imply that endogenous 
TGF- activity maintains normal bone mass by restricting the 
rate of osteoblast maturation through Smad-directed blockade   
of BMP signaling (Maeda et al., 2004). Similarly, genetic studies 
in mice have not directly interrogated the physiological contribu-
tion of matrix-bound TGF- and BMP signals to bone modeling   
bone matrix calibrates the threshold levels of local TGF- 
and BMP signals during osteoblast maturation; and they have 
excluded that fibrillin microfibrils are required to constitute a 
mineralization-competent bone matrix (Fig. 9). Two broader 
conclusions can be drawn from this and our previous studies of 
microfibril mutant mice (Arteaga-Solis et al., 2001; Neptune 
et al., 2003; Carta et al., 2006; Habashi et al., 2006). First, 
fibrillin proteins control in a different manner and with dis-
crete cellular outcomes the bioavailability of local TGF- and 
BMP ligands during tissue formation and remodeling. Second,   
fibrillin assemblies impart contextual specificity to TGF- and 
BMP signals by either concentrating the ligands at sites of 
intended function in the developing embryo (positive regula-
tion, as exemplified by syndactyly in Fbn2
/ mice) or by re-
stricting their gradual release during postnatal tissue modeling 
and remodeling (negative regulation, as exemplified by bone 
loss in Fbn2
/ mice and aortic aneurysm formation in Fbn1 
mutant mice).
Figure 7.  Fibrillin-1 regulates BMP signaling in cultured osteoblasts. (A) Immunodetection of nuclear pSmad1/5/8 accumulation in day 4 differentiating 
WT and Fbn1-null (Fbn1
/) and Fbn2-null (Fbn2
/) cOb cultured in low serum; nuclei are DAPI stained, and histograms summarize the percentage of 
pSmad1/5/8-positive nuclei in WT (black), Fbn1-null (white), or Fbn2-null (gray) cells (n = 3). Bars, 25 µm. (B) Transcriptional activity of pBRE-lux reporter 
plasmid in day 4 differentiating WT, Fbn1-null, and Fbn2-null cOb (n = 5). (C) C2Cl2BRA bioassay measuring BMP signaling in conditioned media from 
WT, Fbn1-null, and Fbn2-null cOb and from the first two cell cultures treated with either 1 µg/ml noggin or 1 µM SB431542 (n = 3). (D and E) qPCR 
estimates of Bmp transcripts in day 4 Fbn1
/ and Fbn2
/ cOb cultures, respectively (n = 3). Error bars indicate mean ± SD, and asterisks indicate 
statistically significant differences (P < 0.05).1117 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
(Ramirez, 2009). Fbn2-null osteoblasts are unable to assemble   
a mineralization-competent (collagen-rich) ECM, conceivably   
because promiscuous TGF- activity delays the emergence of   
osterix-producing cells. Strong support for this conclusion in-
cludes in vivo cell-marking evidence showing that Fbn2
/ 
bones contain significantly fewer osteoblasts expressing Col1a2 
and cell culture data documenting the ability of Fbn2-null cOb 
to respond to TGF- antagonism by reactivating Osx and Col1a2 
expression and resuming matrix mineralization. Along the same 
lines, others have reported that collagen production is repressed 
in Osx
/ mice (which lack differentiated osteoblasts; Wang   
et al., 2006) and stimulated in p53
/ mice (which display Osx 
up-regulation and high bone mass; Nakashima et al., 2002)   
and that a homozygous osterix mutation causes the collagen I– 
related condition osteogenesis imperfecta (Lapunzina et al., 2010). 
Increased latent TGF- activation in Fbn2-null cOb has no appar-
ent effect on cell proliferation. This somewhat surprising result is 
at least consistent with early in vitro analyses suggesting that exog-
enous TGF- modulates cOb proliferation and collagen I pro-
duction through different mechanisms, which are in part influenced 
by ligand concentration (Centrella et al., 1987). Our finding may 
also reflect the involvement of other signaling pathways that are 
stimulated as a result of promiscuous TGF- activity and/or a 
structurally impaired ECM (Carta et al., 2009). Experimental con-
text may also reconcile the unremarkable levels of Runx2 mRNA 
observed in Fbn2-null cOb and the down-regulation of Runx2 
transcription previously reported in TGF-–treated osteoblastic 
cells (Alliston et al., 2001).
Genetic interaction between fibrillin-2 and BMP7 in the 
forming mouse limbs originally predicted that extracellular micro-
fibrils might control the bioavailability of other TGF- family 
members (Arteaga-Solis et al., 2001). This prediction was subse-
quently corroborated by in vitro binding assays showing that the 
prodomain of several BMPs can bind with comparable affinity to 
the N-terminal regions of both fibrillin-1 and -2 (Sengle et al., 
2008b). Additional analyses have led to the proposal that fibril-
lins may act as storage scaffolds that distribute, concentrate, and 
confer latency to BMPs conceivably in a stage and tissue- 
specific manner (Gregory et al., 2005; Sengle et al., 2008a). Our 
finding that maturing Fbn1-null osteoblast cultures are charac-
terized by elevated BMP signaling, less matrix-bound BMP, and 
and  remodeling.  In  this  respect,  Fbn-null  mice  are  the  first   
animal models to yield unambiguous insights into the importance   
of the architectural matrix in modulating the local threshold levels 
of TGF- and BMP signals during osteogenic differentiation.
Dynamic changes in ECM composition accompany and 
influence bone formation and mineralization. Collagens I and III, 
fibronectin, fibrillins, and large proteoglycans predominate in 
the matrix of osteoprogenitor cells; as preosteoblasts cease to 
proliferate and begin to differentiate, collagen I production in-
creases substantially along with continued expression of fibril-
lins and secretion of small proteoglycans and matricellular 
proteins; once fully differentiated, osteoblasts produce osteocalcin 
Figure 8.  Microfibrils are not a structural substrate for matrix mineraliza-
tion. (A) Illustrative von Kossa–stained WT cOb cultures in which Fbn1 or 
Fbn2 expression was silenced by RNAi with histograms on the immediate 
and far right showing the number of mineralized nodules and levels of 
indicated transcripts (n = 3), respectively. (B) Illustrative von Kossa–stained 
Fbn2
/ cOb cultures in which Fbn1 was silenced with histograms on the 
immediate and far right, showing the number of mineralized nodules and 
levels of indicated transcripts, respectively (n = 3). Error bars indicate mean ± 
SD, and asterisks indicate statistically significant differences (P < 0.05).
Figure 9.  Model of microfibril-mediated control of osteoblast maturation. 
The scheme summarizes the distinct contributions of osteoblast-produced 
fibrillin-1 and fibrillin-2 microfibrils to osteogenic differentiation through the 
differential regulation of endogenous TGF- and BMP signals that together 
calibrate the rate of bone formation.JCB • VOLUME 190 • NUMBER 6 • 2010   1118
Sabatier et al., 2009). Moreover, the finding that fibrillin-2 mole-
cules become gradually embedded within fibrillin-1 microfibrils 
during matrix maturation supports the notion that the dynamics 
of microfibril assembly may also determine the spatial distribu-
tion of signaling complexes within the ECM (Charbonneau   
et al., 2003, 2010). In this view, the tridimensional arrangement 
of fibrillin microfibrils may specify both the timely release and 
the optimal concentration of individual TGF- family members 
and ultimately the proper behavior of resident cells, such as osteo-
blasts and osteoclasts during bone remodeling and fracture heal-
ing. In line with this postulate, our parallel study has implicated 
the fibrillins in modulating bone resorption as well through   
osteoblast-supported osteoclastogenesis (Nistala et al., 2010).   
In conclusion, this study has yielded important new insights into 
the extracellular control of local TGF- and BMP signaling and 
implicitly, into the molecular pathophysiology of human dis-
eases that are associated with primary or secondary deficits of 
the bone matrix.
Materials and methods
Histology and histomorphometry
Fbn1
/ and Fbn2
/ mice have been described previously (Arteaga-Solis 
et al., 2001; Carta, et al., 2006); transgenic mice pOBCol2.3GFP and 
Osx-GFP::Cre were provided by D. Rowe (University of Connecticut Health 
Center,  Farmington,  CT)  and  A.  McMahon  (Harvard  University,  Cam-
bridge, MA), respectively (Kalajzic et al., 2005; Rodda and McMahon, 
2006).  Undecalcified  vertebrae  were  embedded  in  methylmethacrylate, 
7-µm-thick methylmethacrylate sections were stained with von Kossa, and 
6-µm paraffin sections of femoral growth plates and calvariae were stained 
with hematoxylin/eosin and van Gieson, respectively, according to stan-
dard protocols. Lumbar vertebrae and femora of WT and mutant mice were 
isolated and scanned using a µCT system (eXplore Locus SP; GE Health-
care) with an isotropic voxel resolution of 9 µm in all three dimensions. All 
scans were performed using a density calibration phantom containing air, 
water, and a hydroxyapatite standard (SB3; Gammex RMI) to allow sub-
sequent determinations of tissue mineral densities. Images were analyzed 
using  data  acquisition  software  (Evolver;  GE  Healthcare),  image  recon-
struction software (Beam; GE Healthcare), and visualization and analysis 
software (Microview; GE Healthcare). To measure BFR, mice were injected 
with 25 mg/kg calcein 10 and 2 d before being sacrificed. Osteoblast 
number, BFR, and BV/TV were assessed using a microscope (DMLB; Leica) 
and attached color video camera (DXC-390; Sony) and the Osteomeasure 
analysis system (Osteometrics). Results were analyzed by an unpaired t test 
(Excel; Microsoft), assuming P < 0.05 as significant.
Primary osteoblast cultures
Standard protocols were used to prepare primary cultures of osteoblasts 
and MSCs from the calvariae or long bones of P2–4 or 7-wk-old mutant 
and WT mice, respectively (Bellows et al., 1986). Cells were cultured in 
-MEM containing 10% FBS (HyClone) containing 1% penicillin/strepto-
mycin (Invitrogen). Once confluent (day 0), cells were induced to differenti-
ate by supplementing the culture medium with 50 µg/ml ascorbic acid and 
10 mM -glycerophosphate. The medium was changed every 3 d until 
day 21, when mineral deposits were visualized by von Kossa staining/ 
van  Geison  counterstaining  or  by  Alizarin  red  staining  and  quantified 
with MetaMorph imaging software (MDS Analytical Technologies). The 
same computer-aided quantification was used to examine cOb cultures 
harboring the Osx-GFP::Cre (at day 5 after induction) or pOBCol2.3GFP 
transgene (at day 17 after induction). In some experiments, culture media 
included 100 ng/ml rhBMP-2 (Wyeth Pharmaceuticals), 2 ng/ml rhTGF-1 
(R&D Systems), 1 µM SB431542 (Sigma-Aldrich) or 300 ng/ml neutral-
izing pan–TGF- antibody (R&D Systems), and respective vehicle controls. 
Measurements of cell proliferation and viability and BrdU incorporation 
were performed according to standard protocols (Bonifacino et al., 2004). 
AP activity was measured using a commercial kit (AnaSpec). All cell   
images were acquired using a microscope (Eclipse TE200; Nikon) or a 
dissecting microscope (SMZ645; Nikon) connected to the aforementioned 
digital camera and processed using Photoshop (version 6.01; Adobe). 
normal Bmp mRNA levels is a very strong indication that fibrillin-1 
microfibrils are indeed involved in sequestering BMP ligands in 
the bone matrix. Although heightened BMP signaling in Fbn1-
null osteoblast cultures implies a context-specific mechanism that 
overrides the potential of fibrillin-2 to bind BMPs, it is still possi-
ble that fibrillin-2 might regulate BMP signaling earlier in osteo-
blastogenesis, as our study did not examine whether loss of Fbn2 
expression also impairs BMP-driven osteogenic commitment.   
In line with evidence of competitive LTBP and fibulin binding 
with fibrillin-1 (Ono et al., 2009), one or more ECM molecules 
may compete with BMP prodomains for the N termini of fibrillins 
at different stages of bone matrix assembly. A similar mechanism 
may also explain the reason why dysregulated BMP signaling is 
only seen in the forming digits of Fbn2
/ mice despite abundant 
fibrillin-1 production (Arteaga-Solis et al., 2001). It is also inter-
esting to note that BMP signaling is low in the developing auto-
pods of Fbn2
/ mice (as indicated by the syndactyly phenotype 
of Fbn2
+/;Bmp7
+/ mice; Arteaga-Solis et al., 2001) and high in 
the growing and remodeling bones of Fbn1 mutant mice (as in-
ferred by the BMP bioassay of Fbn1-null osteoblasts; Fig. 7 B). 
Collectively, these observations therefore support the hypothesis 
that extracellular microfibrils can control BMP bioavailability 
(and by extrapolation TGF- bioavailability) both positively or 
negatively depending on developmental and physiological con-
texts and in a fibrillin-specific manner.
Although our findings have clearly established a causal 
relationship between fibrillin synthesis, matrix sequestration of 
TGF- and BMP complexes, and progression of osteogenic dif-
ferentiation, they have also raised several important new ques-
tions about the mechanisms underlying microfibril-mediated 
control of local TGF- and BMP signaling. One question is 
whether  latent  TGF-  activation  in  a  fibrillin-deficient  state 
may reflect greater availability of the substrate to physiologi-
cally normal levels of activators, greater stimulation of activa-
tors by a structurally abnormal matrix or a combination of both 
mechanisms. A corollary to this question is whether or not the 
same mechanism of latent TGF- activation operates in all   
affected tissues of fibrillin mutant mice. This information is par-
ticularly relevant to the clinical management of organ-specific 
manifestations in MFS. Indeed, although systemic inhibition of 
TGF- signaling (via angiotensin receptor blockade) mitigates 
aortic aneurysm progression in MFS mice and patients (Habashi 
et al., 2006; Brooke, et al., 2008), preliminary data suggest that 
angiotensin receptor blockade therapy is ineffective to improve 
osteopenia in Fbn1 mutant mice. As already noted, our study has 
left unresolved the important problem of how potentially equal 
interactions between fibrillins and TGF- family members may 
impart spatiotemporal specificity to signaling events. This ques-
tion is germane to the unresolved issue of how in vitro inter-
actions between fibrillins and several other ECM proteins translate 
into the in vivo assembly of morphologically discrete macro-
aggregates. One attractive possibility is that cells may coordinate 
microfibril biogenesis at the plasma membrane with growth fac-
tor targeting to the ECM, as recent in vitro evidence suggests that 
fibronectin assemblies and cell surface receptors regulate both 
fibrillin polymerization and LTBP incorporation in the matrix 
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activity in cell lysates with a luminometer (TD-20; Turner Designs) as de-
scribed previously (Abe et al., 1994). Resulting reporter gene values (nor-
malized to cell number) were converted into amount of TGF- (pg/ml) by 
comparing them with relative luciferase units of TMLC treated with increasing 
doses of rhTGF-1. BMP bioassays were similarly performed by measuring 
relative luciferase units of C2C12BRA cells incubated with cOb-conditioned 
media as previously described (Zilberberg et al., 2007). To evaluate matrix-
bound TGF-, cells were washed twice with ice-cold PBS and removed using 
a  lysis  buffer  (0.5%  sodium  deoxycholate  and  10  mM  Tris–HCl  buffer,   
pH 8.0, containing 150 mM NaCl and 1% NP-40). Cell debris were removed 
with ice-cold PBS, and total TGF- (activated by adding -MEM containing 
0.1% BSA and heating the tissue culture plate at 80°C for 15 min) was eval-
uated using the TLMC bioassay. To evaluate matrix-bound BMPs, cells were 
washed twice with PBS and removed using a lysis buffer (0.5% Triton X-100 
and 20 mM ammonium hydroxide, pH 7.0). After removing cellular debris 
with ice-cold PBS, matrix-bound BMPs were solubilized into 10 mM Tris–HCl 
buffer containing 2 M urea, 2% SDS, and 10% glycerol, pH 6.8. Diluted 
samples were assayed using the BMP Quantikine kit (R&D Systems). Both 
bioassays were performed with multiple samples in triplicate and evaluated 
using an unpaired t test (Excel). Significant association was defined when   
P < 0.05 compared with control.
Surface plasmon resonance–binding assays
Binding analyses were performed using a BIAcoreX (BIAcore AB) and previ-
ously described recombinant LTBP1 (L1K), LTBP4 (L4K), and fibrillin-2 (rF86) 
peptides (Isogai et al., 2003; Ono et al., 2009). Peptides L1K and L4K 
were covalently coupled to CM5 sensor chips (research grade) using the 
amine coupling kit following the manufacturer’s instructions (BIAcore AB). 
Binding responses caused by analyte interaction with the surface-coupled 
ligand were normalized by subtracting the background binding to plain 
control flow cells. Binding assays were performed at 25°C in 10 mM Hepes 
buffer, pH 7.4, containing 0.15 M NaCl, 2 mM EDTA, and 0.005% vol/vol 
P20 surfactant (HBS-EP buffer; BIAcore AB). Peptide rF86 was diluted in 
HBS-EP buffer and injected at several concentrations and different flow rates 
over immobilized LTBP peptides. The surface was regenerated with a pulse 
of 10 mM glycine, pH 1.7. Kinetic constants were calculated by nonlinear 
fitting (1:1 interaction model with mass transfer) to the association and dis-
sociation curves according to the manufacturer’s instructions (BIAevaluation 
software version 3.0; BIAcore AB). Apparent equilibrium dissociation con-
stants (Kd) were calculated as the ratio of kd/ka.
Online supplemental material
Fig. S1 shows immunoblots of pSmad2/3 and pSmad1/5/8 proteins in   
fibrillin-deficient osteoblasts, collagen accumulation in Fbn1-null bones, AP 
and mineral nodule formation at different stages of Fbn1-null osteoblast mat-
uration, and mineralization of and fibrillin-deficient osteoblast cultures 
treated with rhBMP2 or rhTGF-1. Fig. S2 shows LTBP1 immunostaining 
in Fbn2-null cOb silenced for Fbn1. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201003089/DC1.
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Immunoblots and immunocytochemistry
Osteoblasts were lysed in extraction buffer (50 mM Tris, 150 mM NaCl, 
5 mM EDTA, 0.5% NP-40, and 0.1% Triton X-100) supplemented with   
1 mM NaF, Na2VO3, 1 mM PMSF, and 1 µg/ml aprotonin, leupeptin, and 
pepstatin. Cell extracts were assayed for total protein content using the 
BCA kit (Thermo Fisher Scientific). Proteins extracts were resolved by 10% 
wt/vol SDS-PAGE and transferred onto Immobilon-P membranes (Millipore). 
Membranes were incubated first with antibody against mouse caspase-3, 
Smad2/3, pSmad2/3, and pSmad1/5/8 (1:1,000 dilution; Cell Signaling 
Technology) or -actin (1:10,000 dilution; Sigma-Aldrich) and subsequently 
with biotin-labeled anti–rabbit IgG (1:25,000 dilution; Jackson Immuno-
Research Laboratories, Inc.) and HRP-conjugated streptavidin (Millipore). 
Nuclear accumulation of pSmads was evaluated by immunofluorescence 
staining of osteoblasts at day 4 after induction that were cultured in 2% 
FBS and subsequently fixed and incubated with antisera against pSmad2/3   
or pSmad1/5/8 at 1:200 dilution and Alexa Fluor 488 or 594 anti–rabbit   
IgG  secondary  antibody  (Invitrogen).  Number  of  pSmad-positive  nuclei 
was calculated on multiple fields and expressed as a percentage of total 
cells in the visual field. Likewise, osteoblast cultures at day 4 after induction 
were used for fibrillin-1, fibrillin-2, and LTBP-1 immunostaining as previously 
described (Charbonneau et al., 2003). Nuclei were visualized with DAPI 
staining. Images were acquired using Axiovision software on an imaging 
electron microscope (Axioplan; Carl Zeiss, Inc.) with the following objec-
tives: Fluar 10×, Plan Apochromat 40×, Plan Neo Fluar 40×, and Plan Apo-
chromat 63× (imaging medium: air for 10, 20, and 40×; and oil for 63×).
Cell transfections and RNAi
Osteoblasts were seeded the day before transfection at a density of 13,000 
cells/cm
2 and cultured in 2% FBS. Cells were transiently cotransfected with 
400 ng p3TP-lux or BRE-luc (provided by J. Massagué [Memorial Sloan-Kettering 
Cancer Center, New York, NY] and P. ten Dijke [Leiden University Medical 
Center, Leiden, Netherlands], respectively; Wrana et al., 1992; Logeart-
Avramoglou et al., 2006) and 1 ng control plasmid SV40 Renilla luciferase 
(Promega) using Lipofectamine 2000 (Invitrogen). Luciferase assays were per-
formed 24 h later and evaluated as previously described (Carta et al., 2009). 
WT or Fbn2-null cObs were transfected with 50 µM siRNA specific for Fbn1, 
Fbn2 (Thermo Fisher Scientific), or Alk5 (Invitrogen) using a nontargeting 
siRNA (Thermo Fisher Scientific) as a control (Carta et al., 2009). Total RNA 
was purified 2 d later and analyzed for gene silencing efficacy as described 
in the next paragraph. Parallel cell cultures were transfected once again 4 d 
later, and osteogenic media were added upon their reaching confluence. All 
experiments were performed using multiple independent samples and in tripli-
cate. Values were analyzed using an unpaired t test, assuming P < 0.05   
as significant.
RNA analyses
Total cellular or calvarial RNA was isolated using RNeasy Mini kit (QIAGEN). 
RNA concentration and purity were determined spectrophotometrically 
(NanoDrop; Thermo Fisher Scientific). Reverse transcription was performed 
with random hexamer primers (Invitrogen) and multiple temperature reverse 
transcription (AffinityScript; Agilent Technologies) using 1 µg total RNA as 
a template according to the manufacturer’s instructions. The cDNAs were 
amplified using SYBR green supermix with ROX (6-carboxy-X-rhodamine; 
Fermentas) on a Mastercycler ep Realplex instrument (Eppendorf). -Actin 
amplification was used as an internal reference for each sample. All qPCR 
primer sets were purchased from SuperArray Bioscience Corporation. Ther-
mal cycling conditions were 95°C for 10 min followed by 40 cycles consist-
ing of 95°C for 15-s denaturation, 60°C for 30-s annealing, and 72°C for 
30-s extension. Comparative quantification was performed using multiple 
biological replicates that were analyzed in triplicate with the same untreated 
WT sample designated as the calibrator across different independent ex-
perimental runs. Statistical significance was evaluated by an unpaired t test,   
assuming significant association at P < 0.05 compared with control samples.
TGF- and BMP bioassays
Cells for TGF- and BMP bioassays were provided by D. Rifkin (New York 
University School of Medicine, New York, NY; Abe et al., 1994; Zilberberg   
et al., 2007). The former bioassays used either cocultures of TMLC and   
osteoblasts (to measure active TGF-) or TMLC incubated in the presence 
of heat-activated conditioned media collected from osteoblast cultures   
(to measure total TGF-). In both cases, cells were cultured at the density of 
83,000 cells/cm
2 on 48-well plates in serum-free DME containing 0.1% 
BSA, and TGF- activity was assessed 16 h later by measuring luciferase JCB • VOLUME 190 • NUMBER 6 • 2010   1120
Karsenty, G., H.M. Kronenberg, and C. Settembre. 2009. Genetic control of bone 
formation. Annu. Rev. Cell Dev. Biol. 25:629–648. doi:10.1146/annurev 
.cellbio.042308.113308
Katagiri, T., T. Suda, and K. Miyazono. 2008. The bone morphogenetic proteins. 
In The TGF- Family. R. Derynck and K. Miyazono, editors. Cold Spring 
Harbor Laboratory Press. Cold Spring Harbor, NY. 121–149.
Kitahama, S., M.A. Gibson, G. Hatzinikolas, S. Hay, J.L. Kuliwaba, A. Evdokiou, 
G.J. Atkins, and D.M. Findlay. 2000. Expression of fibrillins and other 
microfibril-associated proteins in human bone and osteoblast-like cells. 
Bone. 27:61–67. doi:10.1016/S8756-3282(00)00292-1
Lapunzina, P., M. Aglan, S. Temtamy, J.A. Caparrós-Martín, M. Valencia, R. 
Letón, V. Martínez-Glez, R. Elhossini, K. Amr, N. Vilaboa, and V.L. Ruiz-
Perez. 2010. Identification of a frameshift mutation in Osterix in a patient 
with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 87:110–114. 
doi:10.1016/j.ajhg.2010.05.016
Logeart-Avramoglou, D., M. Bourguignon, K. Oudina, P. Ten Dijke, and H. 
Petite. 2006. An assay for the determination of biologically active bone 
morphogenetic proteins using cells transfected with an inhibitor of dif-
ferentiation  promoter-luciferase  construct.  Anal.  Biochem.  349:78–86. 
doi:10.1016/j.ab.2005.10.030
Maeda,  S.,  M.  Hayashi,  S.  Komiya,  T.  Imamura,  and  K.  Miyazono.  2004. 
Endogenous TGF- signaling suppresses maturation of osteoblastic mes-
enchymal cells. EMBO J. 23:552–563. doi:10.1038/sj.emboj.7600067
Mundy, G.R., B. Boyce, D. Hughes, K. Wright, L. Bonewald, S. Dallas, S. 
Harris, N. Ghosh-Choudhury, D. Chen, C. Dunstan, et al. 1995. The   
effects  of  cytokines  and  growth  factors  on  osteoblastic  cells.  Bone.  
17(2, Suppl):71S–75S. doi:10.1016/8756-3282(95)00182-D
Murshed, M., D. Harmey, J.L. Millán, M.D. McKee, and G. Karsenty. 2005. 
Unique coexpression in osteoblasts of broadly expressed genes accounts 
for the spatial restriction of ECM mineralization to bone. Genes Dev. 
19:1093–1104. doi:10.1101/gad.1276205
Nakashima, K., X. Zhou, G. Kunkel, Z. Zhang, J.M. Deng, R.R. Behringer, and 
B. de Crombrugghe. 2002. The novel zinc finger-containing transcription 
factor osterix is required for osteoblast differentiation and bone forma-
tion. Cell. 108:17–29. doi:10.1016/S0092-8674(01)00622-5
Neptune,  E.R.,  P.A.  Frischmeyer,  D.E.  Arking,  L.  Myers,  T.E.  Bunton,  B. 
Gayraud, F. Ramirez, L.Y. Sakai, and H.C. Dietz. 2003. Dysregulation of 
TGF- activation contributes to pathogenesis in Marfan syndrome. Nat. 
Genet. 33:407–411. doi:10.1038/ng1116
Nistala, H., S. Lee-Arteaga, S. Smaldone, G. Siciliano, and F. Ramirez. 2010. 
Extracellular microfibrils modulate osteoblast-supported osteoclastogen-
esis by restricting TGF beta stimulation of RANKL production. J. Biol. 
Chem. doi: 10.1074/jbc.M110.125328. 
Ono, R.N., G. Sengle, N.L. Charbonneau, V. Carlberg, H.P. Bächinger, T. Sasaki, 
S. Lee-Arteaga, L. Zilberberg, D.B. Rifkin, F. Ramirez, et al. 2009. Latent 
transforming growth factor -binding proteins and fibulins compete for 
fibrillin-1  and  exhibit  exquisite  specificities  in  binding  sites.  J.  Biol. 
Chem. 284:16872–16881. doi:10.1074/jbc.M809348200
Pereira, L., S.Y. Lee, B. Gayraud, K. Andrikopoulos, S.D. Shapiro, T. Bunton, 
N.J. Biery, H.C. Dietz, L.Y. Sakai, and F. Ramirez. 1999. Pathogenetic se-
quence for aneurysm revealed in mice underexpressing fibrillin-1. Proc. 
Natl. Acad. Sci. USA. 96:3819–3823. doi:10.1073/pnas.96.7.3819
Quondamatteo, F., D.P. Reinhardt, N.L. Charbonneau, G. Pophal, L.Y. Sakai, 
and  R.  Herken.  2002.  Fibrillin-1  and  fibrillin-2  in  human  embryonic 
and  early  fetal  development.  Matrix  Biol.  21:637–646.  doi:10.1016/ 
S0945-053X(02)00100-2
Ramirez, F. 2009. Extracellular matrix in the skeleton. In The Skeletal System. 
O. Pourquié, editor. Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, NY. 341–353.
Ramirez, F., and E. Arteaga-Solis. 2008. Marfan syndrome and related disor-
ders. In Primer on the Metabolic Bone Diseases and Disorders of Mineral 
Metabolism. Seventh Edition. C.J. Rosen, editor. American Society for 
Bone and Mineral Research Publications, Washington, D.C. 450–454.
Ramirez, F., and H.C. Dietz. 2007. Marfan syndrome: from molecular pathogene-
sis to clinical treatment. Curr. Opin. Genet. Dev. 17:252–258. doi:10.1016/ 
j.gde.2007.04.006
Ramirez, F., and D.B. Rifkin. 2009. Extracellular microfibrils: contextual plat-
forms for TGFbeta and BMP signaling. Curr. Opin. Cell Biol. 21:616–
622. doi:10.1016/j.ceb.2009.05.005
Ramirez, F., and L.Y. Sakai. 2010. Biogenesis and function of fibrillin assem-
blies. Cell Tissue Res. 339:71–82. doi:10.1007/s00441-009-0822-x
Rodda, S.J., and A.P. McMahon. 2006. Distinct roles for Hedgehog and canoni-
cal Wnt signaling in specification, differentiation and maintenance of 
osteoblast progenitors. Development. 133:3231–3244. doi:10.1242/dev 
.02480
Roman-Roman, S., T. Garcia, A. Jackson, J. Theilhaber, G. Rawadi, T. Connolly, 
S.  Spinella-Jaegle,  S.  Kawai,  B.  Courtois,  S.  Bushnell,  et  al.  2003. 
Identification of genes regulated during osteoblastic differentiation by 
R. Derynck and K. Miyazono, editors. Cold Spring Harbor Laboratory 
Press, Cold Spring Harbor, NY. 667–723.
Annes, J.P., J.S. Munger, and D.B. Rifkin. 2003. Making sense of latent TGFbeta 
activation. J. Cell Sci. 116:217–224. doi:10.1242/jcs.00229
Arteaga-Solis, E., B. Gayraud, S.Y. Lee, L. Shum, L.Y. Sakai, and F. Ramirez. 
2001. Regulation of limb patterning by extracellular microfibrils. J. Cell 
Biol. 154:275–281. doi:10.1083/jcb.200105046
Bellows, C.G., J.E. Aubin, J.N. Heersche, and M.E. Antosz. 1986. Mineralized 
bone nodules formed in vitro from enzymatically released rat calvaria cell 
populations. Calcif. Tissue Int. 38:143–154. doi:10.1007/BF02556874
Bonifacino,  J.S.,  M.  Dasso,  J.B.  Harford,  J.  Lippincott-Schwartz,  and  K.M. 
Yamada. 2004. Short Protocols in Cell Biology Science: a Compendium 
of Methods from Current Protocols in Cell Biology. J. Wiley & Sons Inc., 
Hoboken, NJ. 826 pp.
Brooke, B.S., J.P. Habashi, D.P. Judge, N. Patel, B. Loeys, and H.C. Dietz III. 
2008. Angiotensin II blockade and aortic-root dilation in Marfan’s syn-
drome. N. Engl. J. Med. 358:2787–2795. doi:10.1056/NEJMoa0706585
Carta, L., L. Pereira, E. Arteaga-Solis, S.Y. Lee-Arteaga, B. Lenart, B. Starcher, 
C.A. Merkel, M. Sukoyan, A. Kerkis, N. Hazeki, et al. 2006. Fibrillins 1 
and 2 perform partially overlapping functions during aortic development. 
J. Biol. Chem. 281:8016–8023. doi:10.1074/jbc.M511599200
Carta, L., S. Smaldone, L. Zilberberg, D. Loch, H.C. Dietz, D.B. Rifkin, and 
F. Ramirez. 2009. p38 MAPK is an early determinant of promiscuous 
Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J. Biol. 
Chem. 284:5630–5636. doi:10.1074/jbc.M806962200
Centrella, M., T.L. McCarthy, and E. Canalis. 1987. Transforming growth fac-
tor  is a bifunctional regulator of replication and collagen synthesis 
in osteoblast-enriched cell cultures from fetal rat bone. J. Biol. Chem. 
262:2869–2874.
Charbonneau, N.L., B.J. Dzamba, R.N. Ono, D.R. Keene, G.M. Corson, D.P. 
Reinhardt, and L.Y. Sakai. 2003. Fibrillins can co-assemble in fibrils, 
but fibrillin fibril composition displays cell-specific differences. J. Biol. 
Chem. 278:2740–2749. doi:10.1074/jbc.M209201200
Charbonneau,  N.L.,  C.D.  Jordan,  D.R.  Keene,  S.  Lee-Arteaga,  H.C.  Dietz, 
D.B.  Rifkin,  F.  Ramirez,  and  L.Y.  Sakai.  2010.  Microfibril  structure 
masks fibrillin-2 in postnatal tissues. J. Biol. Chem. 285:20242–20251. 
doi:10.1074/jbc.M109.087031
Chen, Q., P. Sivakumar, C. Barley, D.M. Peters, R.R. Gomes, M.C. Farach-
Carson, and S.L. Dallas. 2007. Potential role for heparan sulfate proteo-
glycans in regulation of transforming growth factor- (TGF-) by 
modulating assembly of latent TGF--binding protein-1. J. Biol. Chem. 
282:26418–26430. doi:10.1074/jbc.M703341200
Dallas, S.L., P. Sivakumar, C.J.P. Jones, Q. Chen, D.M. Peters, D.F. Mosher, 
M.J.  Humphries,  and  C.M.  Kielty.  2005.  Fibronectin  regulates  latent 
transforming growth factor- (TGF ) by controlling matrix assembly of 
latent TGF -binding protein-1. J. Biol. Chem. 280:18871–18880. doi:10 
.1074/jbc.M410762200
Ducy, P., R. Zhang, V. Geoffroy, A.L. Ridall, and G. Karsenty. 1997. Osf2/Cbfa1: 
a transcriptional activator of osteoblast differentiation. Cell. 89:747–754. 
doi:10.1016/S0092-8674(00)80257-3
Gregory,  K.E.,  R.N.  Ono,  N.L.  Charbonneau,  C.L.  Kuo,  D.R.  Keene,  H.P. 
Bächinger, and L.Y. Sakai. 2005. The prodomain of BMP-7 targets the 
BMP-7 complex to the extracellular matrix. J. Biol. Chem. 280:27970–
27980. doi:10.1074/jbc.M504270200
Habashi, J.P., D.P. Judge, T.M. Holm, R.D. Cohn, B.L. Loeys, T.K. Cooper, L. 
Myers, E.C. Klein, G. Liu, C. Calvi, et al. 2006. Losartan, an AT1 antago-
nist, prevents aortic aneurysm in a mouse model of Marfan syndrome. 
Science. 312:117–121. doi:10.1126/science.1124287
Hubmacher,  D.,  E.I.  El-Hallous, V.  Nelea,  M.T.  Kaartinen,  E.R.  Lee,  and  D.P. 
Reinhardt. 2008. Biogenesis of extracellular microfibrils: Multimerization 
of the fibrillin-1 C terminus into bead-like structures enables self-assembly. 
Proc. Natl. Acad. Sci. USA. 105:6548–6553. doi:10.1073/pnas.0706335105
Isogai,  Z.,  R.N.  Ono,  S.  Ushiro,  D.R.  Keene, Y.  Chen,  R.  Mazzieri,  N.L. 
Charbonneau, D.P. Reinhardt, D.B. Rifkin, and L.Y. Sakai. 2003. Latent 
transforming growth factor -binding protein 1 interacts with fibrillin 
and is a microfibril-associated protein. J. Biol. Chem. 278:2750–2757. 
doi:10.1074/jbc.M209256200
Judge, D.P., N.J. Biery, D.R. Keene, J. Geubtner, L. Myers, D.L. Huso, L.Y. 
Sakai, and H.C. Dietz. 2004. Evidence for a critical contribution of haplo-
insufficiency in the complex pathogenesis of Marfan syndrome. J. Clin. 
Invest. 114:172–181.
Kalajzic, I., A. Staal, W.P. Yang, Y. Wu, S.E. Johnson, J.H. Feyen, W. Krueger, P. 
Maye, F. Yu, Y. Zhao, et al. 2005. Expression profile of osteoblast lineage 
at defined stages of differentiation. J. Biol. Chem. 280:24618–24626. 
doi:10.1074/jbc.M413834200
Kang, J.S., C. Liu, and R. Derynck. 2009. New regulatory mechanisms of TGF-  
receptor  function.  Trends  Cell  Biol.  19:385–394.  doi:10.1016/j.tcb 
.2009.05.0081121 Extracellular regulation of TGF- and BMP signaling • Nistala et al.
genome-wide expression analysis of mouse calvaria primary osteoblasts 
in vitro. Bone. 32:474–482. doi:10.1016/S8756-3282(03)00052-8
Rosen, V., and R.S. Thies. 1992. The BMP proteins in bone formation and repair. 
Trends Genet. 8:97–102.
Sabatier, L., D. Chen, C. Fagotto-Kaufmann, D. Hubmacher, M.D. McKee, D.S. 
Annis, D.F. Mosher, and D.P. Reinhardt. 2009. Fibrillin assembly requires 
fibronectin. Mol. Biol. Cell. 20:846–858. doi:10.1091/mbc.E08-08-0830
Sengle, G., R.N. Ono, K.M. Lyons, H.P. Bächinger, and L.Y. Sakai. 2008a. A 
new model for growth factor activation: type II receptors compete with 
the prodomain for BMP-7. J. Mol. Biol. 381:1025–1039. doi:10.1016/ 
j.jmb.2008.06.074
Sengle, G., N.L. Charbonneau, R.N. Ono, T. Sasaki, J. Alvarez, D.R. Keene, 
H.P. Bächinger, and L.Y. Sakai. 2008b. Targeting of bone morphogenetic 
protein growth factor complexes to fibrillin. J. Biol. Chem. 283:13874–
13888. doi:10.1074/jbc.M707820200
Shi, Y., and J. Massagué. 2003. Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell. 113:685–700. doi:10.1016/S0092-8674 
(03)00432-X
Stein, G.S., J.B. Lian, and T.A. Owen. 1990. Bone cell differentiation: a func-
tionally  coupled  relationship  between  expression  of  cell-growth-  and 
tissue-specific genes. Curr. Opin. Cell Biol. 2:1018–1027. doi:10.1016/0955- 
0674(90)90151-4
ten Dijke, P., and H.M. Arthur. 2007. Extracellular control of TGFbeta signalling 
in vascular development and disease. Nat. Rev. Mol. Cell Biol. 8:857–869. 
doi:10.1038/nrm2262
Ulloa-Montoya, F., B.L. Kidder, K.A. Pauwelyn, L.G. Chase, A. Luttun, A. 
Crabbe,  M.  Geraerts, A.A.  Sharov, Y.  Piao,  M.S.H.  Ko,  et  al.  2007. 
Comparative transcriptome analysis of embryonic and adult stem cells 
with extended and limited differentiation capacity. Genome Biol. 8:R163. 
doi:10.1186/gb-2007-8-8-r163
Wang, X., H.Y. Kua, Y. Hu, K. Guo, Q. Zeng, Q. Wu, H.H. Ng, G. Karsenty, B. de 
Crombrugghe, J. Yeh, and B. Li. 2006. p53 functions as a negative regula-
tor of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and 
bone remodeling. J. Cell Biol. 172:115–125. doi:10.1083/jcb.200507106
Wrana, J.L., L. Attisano, J. Cárcamo, A. Zentella, J. Doody, M. Laiho, X.F. 
Wang, and J. Massagué. 1992. TGF  signals through a heteromeric 
protein kinase receptor complex. Cell. 71:1003–1014. doi:10.1016/0092- 
8674(92)90395-S
Zhang, H., S.D. Apfelroth, W. Hu, E.C. Davis, C. Sanguineti, J. Bonadio, R.P. 
Mecham, and F. Ramirez. 1994. Structure and expression of fibrillin-2, a 
novel microfibrillar component preferentially located in elastic matrices. 
J. Cell Biol. 124:855–863. doi:10.1083/jcb.124.5.855
Zhang, H., W. Hu, and F. Ramirez. 1995. Developmental expression of fibrillin 
genes suggests heterogeneity of extracellular microfibrils. J. Cell Biol. 
129:1165–1176. doi:10.1083/jcb.129.4.1165
Zilberberg, L., P. ten Dijke, L.Y. Sakai, and D.B. Rifkin. 2007. A rapid and sensi-
tive bioassay to measure bone morphogenetic protein activity. BMC Cell 
Biol. 8:41. doi:10.1186/1471-2121-8-41